TABLE 3.
Parameter | All patients (n = 90) | PET-positive (n = 42) | PET-negative (n = 48) |
Median follow-up (mo) | 23 (1–47) | ||
PSA at last follow-up (n) | 90 | 42 | 48 |
Median PSA (ng/mL) | 0.07 (<0.03–4.92) | 0.07 (<0.03–4.92) | 0.07 (0.01–1.3) |
PSA ≤ 0.1 ng/mL | 78% | 74% | 82%, P = 0.377 |
PSA ≤ 0.2 ng/mL | 78% | 74% | 82%, P = 0.662 |
PSA at last follow-up without ADT (n) | 87 | 40 | 47 |
Median PSA (ng/mL) | 0.07 (<0.03–4.92) | 0.07 (<0.03–4.92) | 0.07 (<0.03–1.3) |
PSA ≤ 0.1 ng/mL | 80% | 78% | 82%, P = 0.191 |
PSA ≤ 0.2 ng/mL | 80% | 78% | 82%, P = 0.392 |
Clinical progress | |||
Distant metastases | None | ||
Death | None |
Data in parentheses are ranges.